The anti-depressant effects of a novel PDE4 inhibitor derived from resveratrol

References

• Banasr M, Hery M, Printemps R, Daszuta A. 2004. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology. 29(3):450–460.
   PubMed Web of Science ®Google Scholar
• Baur JA, Sinclair DA. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 5(6):493–506.
   PubMed Web of Science ®Google Scholar
• Belluti F, Fontana G, Dal Bo L, Carenini N, Giommarelli C, Zunino F. 2010. Design, synthesis and anticancer activities of stilbene-coumarin hybrid compounds: identification of novel proapoptotic agents. Bioorg Med Chem. 18(10):3543–3550.
   PubMed Web of Science ®Google Scholar
• Biasutto L, Mattarei A, Sassi N, Azzolini M, Romio M, Paradisi C, Zoratti M. 2014. Improving the efficacy of plant polyphenols. Anticancer Agents Med Chem. 14(10):1332–1342.
   PubMed Web of Science ®Google Scholar
• Biasutto L, Mattarei A, Azzolini M, La Spina M, Sassi N, Romio M, Paradisi C, Zoratti M. 2017. Resveratrol derivatives as a pharmacological tool. Ann N Y Acad Sci. 1403(1):27–37.
   PubMed Web of Science ®Google Scholar
• Chen LW, Wang YQ, Wei LC, Shi M, Chan YS. 2007. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. CNS Neurol Disord Drug Targets. 6(4):273–281.
   PubMedGoogle Scholar
• Coimbra M, Isacchi B, van Bloois L, Torano JS, Ket A, Wu X, Broere F, Metselaar JM, Rijcken CJ, Storm G, Bilia R, et al. 2011. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int J Pharm. 416(2):433–442.
   PubMed Web of Science ®Google Scholar
• Cote RH, Feng Q, Valeriani BA. 2003. Relative potency of various classes of phosphodiesterase (PDE) inhibitors for rod and cone photoreceptor PDE6. Invest Ophthalmol. 44:1524–1527.
   Google Scholar
• Fulda S. 2010. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today. 15(17–18):757–765.
   PubMed Web of Science ®Google Scholar
• Kang SS, Cuendet M, Endringer DC, Croy VL, Pezzuto JM, Lipton MA. 2009. Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1, COX-2 and NF-kappaB. Bioorg Med Chem. 17(3):1044–1054.
   PubMed Web of Science ®Google Scholar
• Kleppisch T. 2009. Phosphodiesterases in the central nervous system. Handb Exp Pharmacol. 191:71–92.
   Google Scholar
• Li W, Ling S, Yang Y, Hu Z, Davies H, Fang M. 2014. Systematic hypothesis for post-stroke depression caused inflammation and neurotransmission and resultant on possible treatments. Neuro Endocrinol Lett. 35(2):104–109.
   PubMed Web of Science ®Google Scholar
• Mazue F, Colin D, Gobbo J, Wegner M, Rescifina A, Spatafora C, Fasseur D, Delmas D, Meunier P, Tringali C, et al. 2010. Structural determinants of resveratrol for cell proliferation inhibition potency: experimental and docking studies of new analogs. Eur J Med Chem. 45(7):2972–2980.
   PubMed Web of Science ®Google Scholar
• Menniti FS, Faraci WS, Schmidt CJ. 2006. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov. 5(8):660–670.
   PubMed Web of Science ®Google Scholar
• Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo HB, Ke HM, Rehmann H, Taussig R, Brown AL, et al. 2012. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 148(3):421–433.
   PubMed Web of Science ®Google Scholar
• Polster BM, Fiskum G. 2004. Mitochondrial mechanisms of neural cell apoptosis. J Neurochem. 90(6):1281–1289.
   PubMed Web of Science ®Google Scholar
• Porsolt RD, Bertin A, Jalfre M. 1978. “Behavioural despair” in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol. 51(3):291–294.
   PubMed Web of Science ®Google Scholar
• Ranney A, Petro MS. 2009. Resveratrol protects spatial learning in middle-aged C57BL/6 mice from effects of ethanol. Behav Pharmacol. 20(4):330–336.
   PubMed Web of Science ®Google Scholar
• Schoepf D, Uppal H, Potluri R, Chandran S, Heun R. 2014. Comorbidity and its relevance on general hospital based mortality in major depressive disorder: a naturalistic 12-year follow-up in general hospital admissions. J Psychiatr Res. 52:28–35.
   PubMed Web of Science ®Google Scholar
• Shaywitz AJ, Greenberg ME. 1999. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem. 68:821–861.
   PubMed Web of Science ®Google Scholar
• Silove D, Alonso J, Bromet E, Gruber M, Sampson N, Scott K, Andrade L, Benjet C, Miguel J, de Almeida C, et al. 2015. Pediatric-onset and adult-onset separation anxiety disorder across countries in the world mental health survey. Am J Psychiatry. 172(7):647–656.
   PubMed Web of Science ®Google Scholar
• Takahashi J, Palmer TD, Gage FH. 1999. Retinoic acid and neurotrophins collaborate to regulate neurogenesis in adult-derived neural stem cell cultures. J Neurobiol. 38(1):65–81.
   PubMedGoogle Scholar
• Tredici G, Miloso M, Nicolini G, Galbiati S, Cavaletti G, Bertelli A. 1999. Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant? Drugs Exp Clin Res. 25(2–3):99–103.
   PubMedGoogle Scholar
• Wang G, Chen L, Pan XY, Chen JC, Wang LQ, Wang WJ, Cheng RC, Wu F, Feng XQ, Yu YC, et al. 2016. The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling. Oncotarget. 7(14):17380–17392.
   PubMedGoogle Scholar
• Young RA, Ward AM. 1988. Milrinone. A preliminary review of its pharmacological properties and therapeutic use. Drugs. 36(2):158–192.
   PubMed Web of Science ®Google Scholar
• Yu Y, Wang R, Chen C, Du X, Ruan L, Sun J, Li J, Zhang L, O'Donnell JM, Pan J, et al. 2013. Antidepressant-like effect of trans-resveratrol in chronic stress model: behavioral and neurochemical evidences. J Psychiatr Res. 47(3):315–322.
   PubMed Web of Science ®Google Scholar
• Zhang LM, Qiu ZK, Zhao N, Chen HX, Liu YQ, Xu JP, Zhang YZ, Yang RF, Li YF. 2014. Anxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in animal models of post-traumatic stress disorder. Int J Neuropsychopharmacolgy. 17(10):1659–1669.
   PubMed Web of Science ®Google Scholar
• Zhao P, Chen SK, Cai YH, Lu X, Li Z, Cheng YK, Cui CX, Hu XP, He XX, Luo HB. 2013. The molecular basis for the inhibition of phosphodiesterase-4D by three natural resveratrol analogs. Isolation, molecular docking, molecular dynamics simulations, binding free energy, and bioassay. Biochim Biophys Acta. 1834(10):2089–2096.
   PubMed Web of Science ®Google Scholar